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The aim of this survey was to analyse the standard of care in diagnostic, surgery, chemotherapy and aftercare management for
patients with borderline tumours of the ovary (BOTs) in Germany. A structured questionnaire comprising different dimensions was
sent to all 1114 gynaecological departments. The questionnaire could be returned anonymously. The overall response rate was 29.0%
(323 departments). Most departments were on secondary care (71.8%), tertiary care (23.2%) or university hospital (5.0%) level. Most
clinicians performed not more than five BOT operations (89.2%) per year. Most departments (93.2%) used in addition to classical
bimanual examination and vaginal ultrasound, tumour marker CA-125 detection, CT scan, MRI or PET-CT techniques. Departments
in university and tertiary care hospitals performed more often a fresh frozen section (87 vs 64%). In young women, clinicians
performed much seldom unilateral salpingo-oophorectomy (92%) and only in 53% biopsies of the contralateral ovary. Generally,
biopsies of the contralateral ovary were performed in 4–53% of the patients. Chemotherapy was mostly favoured in ‘high-risk’
patients with tumour residual, microinvasion or invasive implants. Thus, a high grade of insecurity in diagnostic and therapy of BOT
exists in some gynaecological departments and underlines the need for more educational and study activities.
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Borderline tumours of the ovary (BOTs) are a specific
tumour entity that represents some characteristics of malignant
ovarian tumours, but which does not show any destructive
stromal invasion. Thus, the borderline tumour – in contrast to
that of an invasive ovarian carcinoma – has generally had an
excellent prognosis (Sehouli et al, 2005a,b; Tinelli et al, 2006;
Skirnisdottir et al, 2008). Borderline tumours of the ovary
constitute 8–10% of all ovarian tumours. Having an incidence of
1.8–4.8 out of 100000 women per year, they belong to the seldom
‘non-benign’ epithelial ovarian tumours (Hart, 2005; Tinelli et al,
2006; Wong et al, 2007). In contrast to the case of ovarian
carcinomas, most of the patients are diagnosed at an early stage I
(Gotlieb et al, 2005; Yokoyama et al, 2006; Cusido et al, 2007).
Today no specific diagnostic method is able to discriminate
reliably between an early carcinoma of the ovary and a borderline
tumour (Seidman et al, 2004; Hart, 2005; Sehouli et al, 2005a,b;
Kurman et al, 2008). For many years, BOT of the ovary was
considered to be a pre-malignant disease. On the basis of clinical,
pathological and molecular genetic studies, different new models
of ovarian carcinogenesis are being established (Sherman et al,
2004; Denkert and Dietel, 2005; Meinhold-Heerlein et al, 2005;
Kurman et al, 2008). According to Denkert and Dietel (2005),
G1 ovarian carcinomas originate step by step from a cystadenoma
or a borderline tumour. In contrast to this, moderate (G2) and
poorly differentiated (G3) ovarian carcinomas seem to result
from a ‘de novo synthesis’ of a highly malignant tumour, which
skips these ‘developmental steps’. Kurman et al (2008) differ
also between type I tumours presenting slow growing, confined
to the ovary and most originating from borderline tumours. Type
II tumours are rapidly growing, highly aggressive neoplasms
characterised by TP53 mutations and a high level of genetic
instability.
The detection of extraovarian invasive implants determines to a
great extent the prognosis of borderline ovarian tumours (Denkert
and Dietel, 2005; Sehouli et al, 2005a,b). Usually, in most patients
with BOT, non-invasive implants are common, whereas 6% of the
women present invasive implants, which are strongly associated
with a poorer prognosis (Longacre et al, 2005). In the clinical
management, the observation of non-invasive implants appears
to have no influence on survival or on any clinical
consequence (Jones, 2006; Rollins et al, 2006; Silva et al, 2006;
Chang et al, 2008).
Although most part of BOT therapy was strongly oriented
towards the ovarian cancer treatment (Suh-Burgmann, 2006;
Tinelli et al, 2006; Cadron et al, 2007), adjuvant systemic
chemotherapy is nowadays not generally indicated (Boran et al,
2005; Sehouli et al, 2005a,b; Romagnolo et al, 2006; Wong et al,
2007; Yinon et al, 2007).
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sIn contrast to ovarian cancer (du Bois et al, 2001, 2005), no
surveys have yet been carried out in regard to the clinical
management of BOT in Germany.
A structured survey about the current clinical management of
BOTs is deemed absolutely necessary to gain new approaches in the
conception of prospective trials and to identify the demand for
further education and research activities concerning the topic of BOT.
MATERIALS AND METHODS
Over a period of 12 months, a questionnaire concerning the
therapy management of BOT was sent by conventional post to a
total of 1135 clinics in Germany. These included all university
hospitals, hospitals of tertiary or secondary medical care and
public community general practitioners’ clinics (a special subtype
of secondary care institutions in Germany entailing considerable
involvement with the general practitioners in the inpatient
management). The mail questionnaires were sent directly to the
heads of the department of obstetrics and gynaecology of each
institution.
The questionnaire was developed in a multistep process
according to similar surveys (Sehouli et al, 2005a,b). First,
relevant topics and a list of questions were formulated by an
expert group including gynaecological oncologists, pathologists
and statisticians (AC, JS, DS and WK) on the basis of a workshop
and according to the national and international guidelines
(German Society of Obstetrics and Gynecology and the National
Cancer Institute). The conceived catalogue of questions was finally
converted into a structured questionnaire. This focused on
statistical data, such as clinical structure and clinical size of the
institutions, number of clinics that were performing surgical and
adjuvant treatment for ovarian and borderline tumours, with the
special focus on diagnosis, therapy, prognosis and follow-up
aspects of BOT. A special consideration was the management of
patients who had desired to preserve fertility. All possible answers
and combinations were provided in a multiple-choice manner.
Before beginning the multicentre survey, the questionnaire,
which included 25 questions, was checked by 20 volunteers, all
medical personnel, for comprehensibility and reproducibility in a
pilot study. Here, the average time needed to fill it out was 11min
(range 6–15min).
A written consent was obtained by the ethics committee of the
Charite ´ – University Hospital.
For statistical evaluation, we used SPSS for Windows (version
14.0 SPSS, Chicago, IL, USA). The present investigation was
carried out for the generation of hypothesis. For this, all analyses
were worked out in a primarily descriptive manner. The U-test of
Mann and Whitney, and alternatively the w
2-test, was used for the
control of significances of unbound random samples. For a level of
significance, the limit was set to 5% (Po0.05).
RESULTS
Of the 1135 clinics that were addressed, 21 had no special
department of gynaecology and were therefore excluded from the
evaluation. Of the remaining 1114 clinics, 328 answered the
questionnaires. This corresponds to a response rate of 29.4%. Only
5 (0.4%) of the questionnaires were not eligible for evaluation as
their answers were either incomplete or unreadable. Out of the 30
university hospitals in Germany contacted, 16 (53%) took part in
the survey.
Clinic structure and clinic size (number of gynaecological
beds)
From all of the questionnaires returned, 5% came from university
clinics (n¼16), 23% from tertiary care hospitals (n¼75%), 65%
from secondary care hospitals (n¼209) and 7% from general
practitioners’ clinics (n¼23).
With respect to the size – that is the number of beds in the
gynaecological departments – the following picture was observed
(one clinic revealed no data): 78 clinics (24%) had a maximum of
30 beds, 155 clinics (48%) had 31–50 beds, 81 hospitals (25%) had
51–100 and only 8 institutes (3%) had more than 100 gynaecology
beds.
Number of ovarian cancer operations
Responding to the question ‘How many patients with ovarian
cancer have you treated in the past 12 months by surgery?’, 5%
answered that they had not undertaken any such surgical
interventions. The majority of the departments (n¼270, 80%)
reported no more than 20 ovarian carcinoma operations per year.
Within 1 year, almost half of the institutions (49%) had done 1–10
and one-third (35%) 11–20 ovarian carcinoma operations,
whereas 17 clinics (5%) treated 21–30 ovarian carcinomas, and
only 20 hospitals (6%) had undertaken more than 30 interventions
per year.
According to the size of the academic departments of
gynaecology and obstetrics, 69% (11 out of 16) treated more than
30 patients with ovarian cancer by surgery and 25% (4 out of 16)
not less than 11 patients per year. The majority of the tertiary care
hospitals (65%) treated 11–30 ovarian carcinomas each year. Only
11% (8 out of 75) of these clinics treated more than 30 women with
ovarian cancer and 24% (18 out of 75) up to 10 women by surgery
in 1 year. The majority of the secondary care hospitals (59%)
treated no more than 10 ovarian carcinomas per year. In 33% (69
out of 209) of these clinics, 11–20 carcinomas were treated
surgically, in 4% (8 out of 209) 21 or more, and in only 3% (7 out
of 29) no ovarian carcinomas were treated operatively at all. Public
general practitioners’ clinics treated ovarian carcinomas more
seldom than did all other institutions. In 15 of the 23 clinics of this
type (65%), no more than 10 ovarian carcinomas were operated
on, whereby 8 of the hospitals (35%) did not perform any ovarian
cancer surgery at all.
Thus, 287 of the 323 hospitals participating in the survey were
ranked as ‘low-volume clinics’, with 1 to maximal 30 operations
per year, and only 20 institutions as ‘high-volume clinics’, with
more than 30 operations per year (Figure 1). Within the ‘high-
volume clinics’, 95% were university and tertiary care hospitals.
We here detected significantly more surgical interventions in
women with ovarian carcinomas (Po0.05).
The number of surgically treated BOTs
As to the question ‘How many BOTs have you operated on in the
last 12 months?’ 157 of the replies (48.6%) reported a maximum of
2 and 131 (40.6%) reported 3–5 borderline tumour operations.
From the 323 participants, 30 (9%) treated 6–10 BOTs by surgery
per year and only 3 departments (0.9%) more than 10. Two clinics
(0.6%) submitted no statements.
Analysing the number of surgical interventions per year with
respect to the clinic type, we observed that 31% (5 out of 16) of the
university hospitals performed 3–5 BOT operations, 56% (9 out of
16) 6–10 and 6% (1 out of 16) more than 10 BOT operations per
year. One department reported a maximum of two operations of
borderline tumours each year.
Among the tertiary care hospitals, we encountered the following
situation: 56% (42 out of 75) of the clinics operated within 1 year
3–5 BOTs, 16% (12 out of 75) 6–10 and only one clinic (1.3%)
more than 10 borderline tumours. The majority of the secondary
care hospitals (57%) treated less than 2 BOTs a year, whereas 80
departments (38%) performed 3–5 and 10 (5%) more than 6 BOT
operations per year. Of the 23 public general practitioners’ clinics,
Clinical management of borderline tumours of the ovary
A Coumbos et al
1732
British Journal of Cancer (2009) 100(11), 1731–1738 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s78% (18 out of 23) undertook an operative treatment of maximal 2
borderline tumours and 17% (4 out of 23) 3–5 operations per year.
The analysis of the operation volume – ‘high-volume clinics’
(45 BOT operations per year) compared with ‘low-volume clinics’
(1–5 BOT operations per year) with respect to the clinic size –
showed that 30% of the BOT operations were performed at
university institutions, 40% at tertiary care hospitals and 30% at
secondary care hospitals (Figure 2). Thus, statistically seen, most
patients operated on BOT were treated in university and tertiary
care clinics than in all of the smaller clinics (Po0.05).
Pre-operative diagnostics
When asked the question ‘Which pre-operative diagnostics were
performed at your department in a case of suspicious ovarian
tumour?’, 93% (301) of the participants answered that in addition
to gynaecological examination and vaginal ultrasound in the case
of an unclear ovarian tumour, further diagnostic procedures had
to be performed. The most common additional imaging methods
used were 76% CT scan, 66% Doppler ultrasound, 36% MRI scan
and 1.7% PET-CT scan. One of the most commonly used
diagnostic methods (95%) was the detection of tumour markers
(CEA und CA-125).
The routine detection of the tumour marker was performed
equally often in all participating departments: in 93% of the
universities’ vs 95% of the other clinics (NS). Also, among the use
of Doppler sonography, we observed no differences (60 vs 67%;
NS). In contrast, university clinics performed CT scans much more
seldom than did non-university clinics (40 vs 78%; P¼0.003).
Also, MRI was applied only in a limited number of cases in
university clinics (20 vs 37%), although this difference was not
significant (NS). The PET-CT scan was generally not applied as an
additional diagnostic in the case of supposed ovarian tumours in
the universities’, but it was in 2% of the non-university clinics
(NS).
‘Which was the most common diagnosis suspected in the case
of BOT prior to the operation?’
For this question, 54% of the interviewed participants replied
that before the operation they diagnosed an ‘unclear ovarian
tumour’. For 28% of the interviewers, an ovarian carcinoma, and
for 20%, a benign ovarian tumour was suspected. Only in 8.4% of
the cases was the pre-operative diagnosis that of a borderline
tumour. Some of the clinics (3.4%) did not answer this question.
We did not ascertain any statistical differences according to the
clinic types observed in the survey.
Type and radicality of surgical intervention
As to the question ‘Which operation techniques were used for the
diagnosis of BOT?’ 48% of the clinicians were found to use
conventional laparotomy. Primary endoscopy was the basis for the
diagnosis of 15% of the BOTs, whereas 19% used a diagnostic
laparoscopy, followed by completion of the operation in a second
intervention. A switch from laparoscopy to laparotomy during the
primary surgical intervention was performed by 18% of the clinics.
In the university clinics, 53% of the BOT diagnoses occurred
after laparotomy and 20% after laparoscopy. In 7%, after
diagnostic laparoscopy, the tumour resection was performed by
laparotomy in the same session, but 21% preferred a subsequent
operative intervention. Tertiary care hospitals (n¼75) showed a
similar surgical management: 53% laparotomy, 12% laparoscopy,
16% diagnostic laparoscopy with a following switch to laparotomy
and 18% laparotomy in a second intervention. In secondary care
hospitals (n¼209), 47% of the BOT cases were diagnosed and
treated by primary laparotomy, 14% by laparoscopy, 18% by
laparoscopic diagnosis and joined switch to laparotomy, and 20%
performed laparotomy in a subsequent intervention. Public
general practitioners’ clinics (n¼23) usually preferred the primary
laparotomy (40%) followed by primary laparoscopy (26%),
laparoscopy with switch to laparotomy (25%) and the uncommon
subsequent laparotomy for completion (9%).
In regard to the clinical structure and type here, no significant
differences in the surgical procedures were noted (NS).
Fresh frozen section as an intraoperative diagnostic tool
Regarding the question ‘Did you perform any fresh frozen section
intraoperatively to confirm the diagnosis of a BOT?’, 68% of the
clinicians confirmed the importance of the intraoperative diag-
nostic. In 87% of the university clinics, 80% of the tertiary care
hospitals, 68% of the secondary care hospitals and 64% of the
general practitioners’ clinics, regular fresh frozen examination was
the standard for intraoperative diagnosis (Figure 3).
Number of surgically treated BOTs per year
288 Low-volume clinics 
(1–30 operations/year)
32 High-volume clinics 
(>5 operations/year)
Tertiary care hospital
(n=75)
Secondary care hospital
(n=209)
Public general practitioners’
clinic (n=23)
21% (n=62)
8% (n=22) 0% (n=0)
30% (n=10)
40% (n=13)
University hospital
(n=16)
2% (n=6) 30% (n=10)
(n=198)
69%
Figure 2 Hospital category and number of surgically treated BOTs per
year (n¼323, 2 clinics not specified, P¼0.0001).
Number of surgically treated ovarian carcinomas per year
23% (n=67)
5% (n=1)
5% (n=15) 0% (n=0)
40% (n=8)
70% 
(n=200)
Tertiary care hospital
(n=75)
Secondary care hospital
(n=209)
Public general practitioners’
clinic (n=23)
287 Low-volume clinics 
(1–30 operations/year)
University hospital
(n=16)
2% (n=5) 55% (n=11)
20 High-volume clinics
(>30 operations/year)
Figure 1 Hospital category and number of surgically treated ovarian
carcinomas per year (n¼323, 1 clinic not specified, 15 clinics did not
perform any operations within the time of evaluation, P¼0.0001).
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the clinics performed the complete tumour resection during the
same operation. In 56%, this approach led to a subsequent surgical
intervention in cases where the primary diagnosis was still not
clear. In all, 25% of the clinicians favoured in general a second
surgical intervention for completion, whereas 4% did not offer any
answer.
Surgical management in case of BOT
To evaluate the operative management in case of BOT, we had
asked ‘Which procedures would you prefer in the surgical therapy
of BOT?’ We here differentiated between three groups of patients:
pre-menopausal, post-menopausal and women in the reproductive
age, who still desired to preserve fertility (Figure 4).
Concerning the operative procedures taken for pre-menopausal
women with a BOT, 99% of all participants performed a unilateral
adnexectomy and 34% a bilateral adnectomy. In university clinics,
a bilateral adnectomy was performed more often (56%) than
in the other clinics: tertiary care hospitals 35%, secondary care
hospitals 34% and general clinics 17% (NS). Instead, among
practitioners’ non-university clinics, a biopsy from the contral-
ateral ovary was favoured. Hysterectomy was observed in 42% of
the clinics and appendectomy in 35%. Omentectomy was
performed in 62%, a rate much more strongly preferred at the
universities’ clinics (88%, P¼0.002) than at tertiary care (76%),
secondary care (56%) or general practitioners’ hospitals (52%).
Peritoneal biopsies were performed in 94% of the university
clinics, 83% of the tertiary care hospitals, 70% of the secondary
care hospitals and 43% of the general practitioners’ clinics.
Samples of peritoneal cytology were collected by 92% of the
clinics. A pelvic lymph node dissection followed in 18.9% of the
surgical interventions.
For post-menopausal patients, the unilateral adnectomy was
performed in 99% of the cases; however, the bilateral adnexectomy
was much common here, being used in 98% (Po0.05%).
Additional hysterectomy (93%) and omentectomy (73%) were
also standard procedures. Omentectomy was observed without any
exception (100%) in all participating university departments, in
84% of the tertiary care, in 69% of the secondary care hospitals and
in 57% of the public general practitioners’ centres (Po0.005).
Peritoneal cytology followed with a total of 94%, and peritoneal
biopsies were collected in 77% of the cases.
For women in the reproductive group with the desire to still
have children, the resection of the concerned ovary followed in
92%; even in 19%, a tumour/ovarian cystectomy was performed.
The contralateral ovary was usually checked by biopsy by 53% of
the participants, but not surgically removed. Much less often were
peritoneal biopsy (67%) and peritoneal wash cytology (86%)
performed (Figure 4). Omentectomy was performed in 81% of the
universities, but only in 57% of the tertiary care units, 31% of the
secondary care units and in as few as 17% of the public general
practitioners’ centres (Po0.05). Peritoneal biopsies were per-
formed in 81 and 80% of the university departments and tertiary
care hospitals, respectively, but only in 64% of the secondary care
and 39% of the general practitioners’ hospitals.
After the patients have declared the wish to have children, 47%
of the clinics recommended a completion of the surgical resection
of the involved ovary and/or contralateral adnectomy. Here, no
significant differences were found between the various profiles of
institutions (NS).
Fresh frozen section examinations according to the hospital category
P=0.153
P=0.152
P=0.726
87%
(n=13)
100%
80%
60%
40%
20%
0%
University
(n=13)
Tertiary care
hospital
Secondary care
hospital
Public general
practitioners’ clinic
80%
(n=56) 68%
(n=135)
64%
(n=14)
(n=70) (n=200) (n=22)
Figure 3 Implementation of the fresh frozen section in the intraopera-
tive diagnosis with respect to the hospital category (n¼323, 16 clinics not
specified).
Surgical management for patients with BOT according to their hormonal status
Unilateral
salpigo-
oophorectomy
Simple
ovqrian
cystectomy
Contralateral
salpingo-
oophorectomy
Biopsy of
contralateral
ovary
Hysterectomy
Appendectomy
Omentectomy LND
pelvis
LND
para-aortal
Peritoneal
biopsy
Peritoneal
lavage
Not specified
100%
50%
0%
99% 98%
4%
42%
93%
73%
77%
7%
20%
99%
34%
47%
42%
35%
62%
72%
5%
92%
19%
53%
21%
38%
67%
1%1% 4%
94% 92%
86%
9%
19%
3%
Pre-menopausal patients Post-menopausal patients Pre-menopausal women with desire to preserve fertility
Figure 4 Surgical management for patients with BOT according to their hormonal status (n¼323, multiple answers are possible).
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treatment of BOT after surgery
For prognostic of the factors that determine a high-risk group of
women with BOT who might otherwise benefit from adjuvant
treatment, most of the interviewees identified the incomplete
tumour resection, the evidence of microinvasive implants and the
tumour stage. Seventy-seven percent of the participants stated that
the detection of microinvasive implants is associated with higher
aggressiveness and a high risk of recurrence, followed by tumour
rest (74%) and advanced stage disease FIGO III (52%) or IV (54%).
Type of adjuvant treatment after primary surgery
Out of all participants, 30% did not recommend an adjuvant
treatment after the primary surgery. In most departments (64%),
chemotherapy was suggested only in the high-risk situation:
tumour residuals, microinvasion with evidence for invasive
implants or in mucinous or clear cell histological subtypes.
Chemotherapy was generally implemented as an adjuvant treat-
ment by only two clinics (0.6%). Few departments (1.5%) preferred
even intraperitoneal (i.p.) chemotherapy, i.p. radionuclide therapy
or whole abdominal irradiation as further treatment options. The
adjuvant treatment was not preferred in 25% of university clinics
(4 out of 16), whereas 12 departments (75%) saw a potential
benefit of chemotherapy for high-risk patients. The majority (46)
of the 75 tertiary care hospitals (62%) would recommend
chemotherapy among risk constellations; the rest of the clinics
(33%) would generally not prefer adjuvant treatment for BOT. One
tertiary care clinic favoured i.p. chemotherapy as an optimal
treatment, whereas only one gynaecological department imple-
mented chemotherapy for all patients with BOT diagnoses. In all,
136 of the 209 secondary care hospitals (65%) considered
chemotherapy as indicative for high-risk patients, 59 hospitals
(28%) generally recommended no adjuvant indication. One
secondary care hospital concluded that chemotherapy was
advisable for all patients with BOT after surgery, and three others
preferred alternative therapy options: i.p. chemotherapy or whole
abdominal irradiation. In 35% of public general practitioners’
hospitals, no adjuvant treatment was recommended, but 48%
preferred chemotherapy for high-risk BOTs. Regarding this
question there were no significant differences noticed in the
treatment management of the institutions participating (NS).
Type of chemotherapy
As to the question ‘Which type of i.v. chemotherapy would you
apply to patients with a BOT?’ 75% said that they favour the
conventional treatment with carboplatin and taxanes. Others (6%)
would prefer a combination of cisplatin and taxanes. Nineteen
percent of the clinicians would treat with carboplatin as a single
agent, and 2.5% would use cisplatin as a single agent. In all, 1.5%
of the clinicians would search for consultation with another
oncological specialist for recommendation.
Management of patients with BOT recurrence
To the question ‘Which treatment is indicated for patients with
relapsed BOT?’ 97% designated surgical treatment as their first
option. Another 64% claimed that chemotherapy was the second
best option here. In contrast to this, only 0.6% considered that
radiation therapy would be a possible treatment. In all, 0.9% of the
interviewees would prefer a consultation with other experts to
obtain decision (Figure 5).
In the university as well as non-university clinics, the therapy of
choice was the radical tumour resection (100 vs 96%). As a second
option, participants chose the application of i.v. chemotherapy (50
vs 65%); here, no statistically significant differences between
university and non-university hospitals were noted (NS).
Aftercare management
In regard to the inquiry ‘How do you organise the aftercare of
patients with BOT?’, most participants specified their recommen-
dation of performing regularly every 3 months a check-up that
includes clinical examinations (96%), gynaecological sonography
(95%) as well as a tumour marker control (67%). For imaging
diagnostic procedures during the aftercare, 28% of the clinicians
used a CT scan, 13% an MRI scan and 2% the PET-CT scan.
Moreover, 26% of the participants considered the second-look
laparoscopy as an adequate method in aftercare management.
With respect to the management of the aftercare recommenda-
tions for women with BOTs, we observed significant differences
between university institutions and other clinics (Figure 6)
(Po0.05). In university clinics, the aftercare includes mostly a
gynaecological examination with sonography, and in one section
of the departments (44%), the routine tumour marker controls. As
opposed to this, all other clinics used CT scan (P¼0.010), tumour
marker control (P¼0.044) and second-look laparoscopy
(P¼0.016) to a significantly higher degree.
Therapeutical options favoured in case of BOT recurrence
Surgery Chemotherapy Radiotherapy Others Consultation Not specified
96.6%
(n=312) 100%
50%
0%
64.1%
(n=207)
0.6%
(n=2)
0.9%
(n=3)
0.9%
(n=3)
2.8%
(n=9)
Figure 5 Management of the recurrence of BOT (n¼323, multiple
answers are possible).
0% (n=0)
100% (n=16) Examination
Sonography
CT scan
MRI scan
PET-CT scan
100% (n=16)
0% (n=0) 2% (n=0)
13% (n=2) 13% (n=40)
30% (n=91)
94% (n=290)
95% (n=293)
Aftercare management
Tumour marker
Second-look
laparoscopy
Not specified 0% (n=0)
0% (n=0)
2% 
27% (n=83)
44% (n=7) 68% (n=209)
University hospitals (n=16)
Tertiary care, secondary care and general practitioners’ clinics (n=307)
Figure 6 Management of aftercare for patients with BOT, with
percentage implementation of diagnostic procedures (n¼323, multiple
answers are possible).
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With this survey, we have performed the first representative
analysis of actual trends and institutional standards for the clinical
management of borderline tumours in Germany.
In the field of pattern of care for women with BOT, only a few
multicentre studies have already been published on an interna-
tional level. Most of these were limited to a monocentric and
retrospective analysis of the incidence, treatment procedures and
they often present only a small number of patients (Boran et al,
2005; Romagnolo et al, 2006; Cusido et al, 2007; Kumpulainen
et al, 2007; Skirnisdottir et al, 2008).
Within all of the 323 clinical departments analysed, the vast
majority treated no more than 30 patients with ovarian carcinoma
per year. These data are in agreement with the recently published
data of the German Gynecological Oncology Group (AGO)
concerning the treatment quality and pattern of care for patients
with ovarian cancer (du Bois et al, 2005). Most of the clinics
reported less than five patients with BOT diagnosis per year. This
finding is in line with national and international incidence data,
where the ratio of patients with ovarian carcinoma to patients with
BOT was between 1:10 and 1:20 (Romagnolo et al, 2006;
Skirnisdottir et al, 2008).
With 29.0% responses to our survey, we have reached a
significant level that allows a representative interpretation of the
data pool examined. Also, the data of the German quality
assurance survey are based on the data of one-third of the patients
treated (du Bois et al, 2005). Nevertheless, for any careful
interpretation of our results, we should not overlook the facts
that there was indeed a limited participation of many hospitals and
also the absence of a significant verifiability of all recommenda-
tions given to our questions (e.g., absence of control of detailed
operation reports, histological diagnosis etc.). Furthermore, we
like to underline that we have not monitored the documentation of
the investigators.
Diagnostics
In most cases, ovarian cancer begins asymptomatically, spreading
in the peritoneal cavity and will then be diagnosed at an advanced
stage during the time of primary diagnosis (FIGO stage III or IV),
whereas the BOT is diagnosed mostly in stage I (Gotlieb et al, 2005;
Sehouli et al, 2005a,b; Yokoyama et al, 2006). Similar to early
carcinomas of the ovary, BOTs are most commonly detected as
accidental histopathological findings after primary surgery for
benign or suspected ovarian mass (Seidman et al, 2004; Jones,
2006; Schem et al, 2007; Chang et al, 2008). In our study, this
applies to 30% of the cases; 28% have their origin in suspected
ovarian tumours and 19.5% arise from a primary benign ovarian
tumour.
On the basis of the current literature, vaginal ultrasound and
possibly additional Doppler ultrasound as well represent the best
diagnostic tool for the detection of BOT (Reles et al, 1997; Cohen
and Fishman, 2002; Togashi, 2003; Schem et al, 2007). Results of
our survey indicate the need for more adequate staging of
borderline tumours in some hospital categories. Especially for
our assessment, this involves the often-used CT and MRI
examinations. Moreover, the commonly observed tumour marker
CA-125 – which is much less enhanced in BOTs than in ovarian
cancers – does not suitably improve any positive or negative
predictive value of the examination (Hart, 2005; Schmalfeldt and
Pfisterer, 2007).
Surgical therapy
The therapy of BOT leans closely on the clinical management of
ovarian carcinoma and is directed at definitive staging, that is
complete or maximum tumour debulking, although the treatment
of BOTs does show some relevant differences (Cadron et al, 2007;
Schmalfeldt and Pfisterer, 2007). According to the FIGO classifica-
tion, the state-of-the-art surgical treatment includes a detailed
exploration of the entire abdomen, bilateral salpingo-oophorect-
omy (BSO), hysterectomy, omentectomy, peritoneal lavage
(or ascites sample) and peritoneal biopsies and resection of all
suspected lesions (Trope et al, 2000; Schmalfeldt and Pfisterer,
2007). For mucinous tumours, an appendectomy should be
performed to exclude any ovarian metastasis of possible mucinous
tumour of the appendix (Lichtenegger et al, 1998; Cadron et al,
2007; Schmalfeldt and Pfisterer, 2007).
The accuracy of the frozen section diagnosis of BOT is very
limited. In the final histological examination, an estimated 23–
27% of all tumours indicated signs of an invasive growth. For
mucinous BOTs, this rate seems to be higher than that for serous
tumours (Hart, 2005). In our study, 56% of all participants
favoured a subsequent interval surgery for those cases where the
intraoperative frozen section was not clear. In comparison with
other clinics, gynaecological departments on university and
tertiary care hospitals performed much more often a fresh frozen
section. Specific factors that pre-determine the specific clinical
management were not asked for in our survey. Here, infrastruc-
tural reasons such as the unavailability of an individual
pathological unit or the principal favour of interval surgery in
case of BOT may have a substantial impact on the surgeon’s
decision in the clinical routine.
As there are often young women in the reproductive age
diagnosed with a BOT who still desire preservation of fertility, all
conservative surgical options must be heeded (Boran et al, 2005;
Marcickiewicz and Brannstrom, 2006; Yinon et al, 2007). Thus, if a
BOT has been diagnosed with no invasive implants, after an
intensive patient consultation, the following procedure can be
chosen: a detailed exploration of the abdomen, a peritoneal lavage,
peritoneal biopsies from all regions of the abdomen, a unilateral
salpingo-oophorectomy (USO), an omentectomy and in addition
for mucinous BOT the appendectomy (Schmalfeldt and Pfisterer,
2007). According to current studies evaluating conservative
surgery in this group, high conception rates were achieved after
a simple ovarian cystectomy (Longacre et al, 2005; Marcickiewicz
and Brannstrom, 2006; Tinelli et al, 2006; Yinon et al, 2007), but
the high risk of local recurrence of up to 75% still limited the
routine implementation (Suh-Burgmann, 2006). Results of cystect-
omy for BOT suggest a higher risk of intraoperative cyst rupture
and of recurrence when compared with USO or BSO (Poncelet
et al, 2006; Yokoyama et al, 2006). For this reason, ovarian
cystectomy or a partial adnexectomy can be performed after a very
careful informing of the patient about the recurrence risk and
providing that the patient is willing to undergo a careful and
prolonged follow-up. Furthermore, the potency of modern
possibilities of maintaining fertility should be always discussed
(Maltaris et al, 2006), whereby cryoconservation of oocytes of
patients with malignant and semi-malignant ovarian tumours still
remains controversial.
For serous tumours, approximately 40% (range 28–66%), and
for mucinous tumours, about 8% (range 0–13%) of the BOTs are
observed to be bilateral (Seidman et al, 2004; Cadron et al, 2007;
Kumpulainen et al, 2007). In this context, we observed that 19% of
the clinical participants performed only unilateral ovarian
cystectomy or at least USO. In a case of unilateral adnectomy, a
biopsy with histologically negative examination of the contralateral
ovary cannot guarantee the detection of possible tumour infiltra-
tion and can induce additional damage of the ovarian tissue, so
that such an operative procedure seems to be dispensable in many
cases. In our survey, the participating clinics indicated a biopsy of
the contralateral side in 4–53% of the cases.
The systematic pelvic and para-aortal lymph node dissection,
which is generally recommended for patients with ovarian cancer
and without post-operative tumour residuals, is however not
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lymph nodes, so called ‘bulky nodes’, can be performed. In
contrast to an ovarian carcinoma, invasion in the lymph nodes and
metastatic spread of BOT are quite seldom and usually non-
invasive (Hart, 2005; Cadron et al, 2007; Kumpulainen et al, 2007).
Moreover, it is not yet clear whether these lymph node
implantations represent real metastases, in situ transformed
secondary muellerian epithelia or hyperplastic mesothelial cells
(Shiraki et al, 1992; Chang et al, 2008). Concerning the performing
of lymph node resection, at least 20% of the patients with FIGO
stage I have to be upgraded as belonging to FIGO stage IIIc, but the
prognostic relevance is in our opinion unimportant (Fauvet et al,
2004; Sehouli et al, 2005a,b; Silva et al, 2006). According to our
results, in 9–20% of the evaluated hospitals, a pelvic, and in 3–7%,
a para-aortal lymph node dissection were performed. These data
are in accordance with other international trials (Fauvet et al, 2004;
Cusido et al, 2007; Kumpulainen et al, 2007).
A general recommendation for completion of the hysterectomy
cannot be suggested because of lack of a validated benefit for the
patients (Fauvet et al, 2004; Cadron et al, 2007; Cusido et al, 2007).
On the one hand, this is due to the fact that following conservative
surgical management for BOT, the patient outcome is still
excellent, but otherwise the rare recurrences usually exhibit a
peritoneal location (Seidman et al, 1998; Trope et al, 2000;
Yokoyama et al, 2006).
Our survey shows clearly the observation that ‘biological’ status
of the patients inside the groups, pre-menopausal, post-menopau-
sal or women in the reproductive age, who desire to preserve
fertility, all have a great influence on conservative or radical
surgical management. Nonetheless, in the group of patients who
wish to preserve their childbearing potential, peritoneal biopsies,
omentectomy and also cytological examinations were performed
much less often, although all guideline recommendations are clear
and these surgical procedures were not found to negatively
influence the fertility (Schmalfeldt and Pfisterer, 2007).
Systemic therapy
So far, there has been no phase III trials performed that explored
the role of systemic therapy for patients with BOT. Generally,
platin-based chemotherapy regimes were administered among
BOT in phase II trials only (Sutton et al, 1991; Gershenson et al,
1998a,b; Seidman et al, 1998; Silva et al, 2006). For women with
stage I disease only, fewer non-randomised trials were performed,
whereby the recurrence rate and patients’ outcome in this group
were even more favourable than those of patients without
chemotherapy (presumably due to the selection of the patients)
(Gershenson et al, 1998a,b; Seidman et al, 1998; Sehouli et al,
2005a,b). This is why the use of adjuvant chemotherapy in patients
without post-operative residuals is nowadays not indicated,
because treatment results without adjuvant therapy have still been
found to be beneficial (Cadron et al, 2007; Schmalfeldt and
Pfisterer, 2007).
The situation of advanced stage BOT, in which post-operative
tumour residuals or invasive implants are present, has to be
discussed in a different manner. Borderline tumours of the ovary
generally have an excellent prognosis. However, patients with
invasive implants and tumour relapse present significantly
decreased survival rates. For these ‘high-risk’ patients, various
authors recommend platin-based chemotherapy regimes
(Gershenson et al,1 9 9 8 a ;S e i d m a net al, 1998; Sehouli et al,
2005a,b). Some authors recommend – upon detection of an invasive
implant – six cycles of platin-based chemotherapy (Gershenson
et al, 1998b), with 15% response rate within patients with post-
operative tumour residual. In our survey, 30% of the participants
found no indication for adjuvant treatment for patients with
advanced stage BOT. Systemic chemotherapy was preferred by only
0.6% of the clinicians interviewed. Most of them (64%) favoured,
however, chemotherapy in complicated disease situations, such as
tumour residual, microinvasion or invasive implants. Intraperito-
neal chemotherapy is absolutely experimental and should not be
applied outside clinical trials. The real effect of systemic
chemotherapy on patient outcome for ‘high-risk’ BOT can only be
truly assessed in randomised international multicentre studies.
CONCLUSION
The results of our multicentre survey underline the high grade of
unsureness in the clinical management of BOT in the clinical day.
To avoid under- and overtreatment of patients with BOT,
educational and training programmes are essential and have to
be intensified. Especially, the group of BOT tumours is seen to be
optimal for the establishment of a multicentre register. This can
also be helpful for a better implementation of evidence-based
guidelines.
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